Clinical Trial Update: Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pharmacokinetics, efficacy, and safety of subcutaneous abatacept in children with active polyarticular juvenile idiopathic arthritis wh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis
• Polyarticular Juvenile Idiopathic Arthritis

Drugs mentioned

• Abatacept (abatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Active Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2016-03-24